Mixed Phase III results for AstraZeneca's Zactima in lung cancer
This article was originally published in Scrip
Executive Summary
AstraZeneca's new multi-targeted anticancer Zactima (vandetanib) has succeeded in a Phase III trial testing it as a second-line therapy in advanced non-small cell lung cancer (NSCLC), in prolonging progression-free survival (PFS), but has failed in two others to meet its primary PFS endpoint. The trials were in patients with both non-squamous and squamous NSCLC.